{"url_path":"/sec/ibo/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1834105/0001493152-26-022512-index.html","accession_number":"0001493152-26-022512","cik":"0001834105","ticker":"IBO","issuer_name":"IMPACT BIOMEDICAL INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1834105/0001493152-26-022512-index.html","primary_entity_key":"0001834105","primary_entity_name":"IMPACT BIOMEDICAL INC."},"word_count":891,"has_tables":true,"body_markdown":"false\nQ1\n--12-31\n0001834105\n\n0001834105\n\n2026-01-01\n2026-03-31\n\n0001834105\n\n2026-05-05\n\n0001834105\n\n2026-03-31\n\n0001834105\n\n2025-12-31\n\n0001834105\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nIBO:BiotechRetailSalesMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:BiotechRetailSalesMember\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001834105\n\nus-gaap:PreferredStockMember\n\n2024-12-31\n\n0001834105\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001834105\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001834105\n\nus-gaap:ParentMember\n\n2024-12-31\n\n0001834105\n\nus-gaap:NoncontrollingInterestMember\n\n2024-12-31\n\n0001834105\n\n2024-12-31\n\n0001834105\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001834105\n\nus-gaap:PreferredStockMember\n\n2025-12-31\n\n0001834105\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001834105\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001834105\n\nus-gaap:ParentMember\n\n2025-12-31\n\n0001834105\n\nus-gaap:NoncontrollingInterestMember\n\n2025-12-31\n\n0001834105\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nus-gaap:PreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nus-gaap:ParentMember\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nus-gaap:NoncontrollingInterestMember\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:PreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:ParentMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:NoncontrollingInterestMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001834105\n\nus-gaap:PreferredStockMember\n\n2025-03-31\n\n0001834105\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001834105\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001834105\n\nus-gaap:ParentMember\n\n2025-03-31\n\n0001834105\n\nus-gaap:NoncontrollingInterestMember\n\n2025-03-31\n\n0001834105\n\n2025-03-31\n\n0001834105\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001834105\n\nus-gaap:PreferredStockMember\n\n2026-03-31\n\n0001834105\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001834105\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001834105\n\nus-gaap:ParentMember\n\n2026-03-31\n\n0001834105\n\nus-gaap:NoncontrollingInterestMember\n\n2026-03-31\n\n0001834105\n\nsrt:SubsidiariesMember\n\n2026-03-31\n\n0001834105\n\nsrt:SubsidiariesMember\n\n2025-12-31\n\n0001834105\n\nsrt:ScenarioPreviouslyReportedMember\n\n2026-03-31\n\n0001834105\n\nus-gaap:SellingGeneralAndAdministrativeExpense\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:SellingGeneralAndAdministrativeExpense\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nIBO:DSSPureAirINCMember\n\n2025-02-25\n2025-02-25\n\n0001834105\n\nus-gaap:AccountsReceivableMember\nIBO:DSSPureAirINCMember\n\n2025-02-25\n\n0001834105\n\nIBO:DSSPureAirINCMember\n\n2025-02-25\n\n0001834105\n\nus-gaap:IntellectualPropertyMember\n\n2025-02-25\n\n0001834105\n\nus-gaap:IntellectualPropertyMember\n\n2025-02-25\n2025-02-25\n\n0001834105\n\nIBO:GlobalBioMedicalIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:GlobalBioMedicalIncMember\n\n2026-03-31\n\n0001834105\n\nIBO:GlobalBioMedicalIncMember\n\n2025-12-31\n\n0001834105\n\nIBO:GlobalBioLifeIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:GlobalBioLifeIncMember\n\n2026-03-31\n\n0001834105\n\nIBO:GlobalBioLifeIncMember\n\n2025-12-31\n\n0001834105\n\nIBO:BioLifeSugarIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:BioLifeSugarIncMember\n\n2026-03-31\n\n0001834105\n\nIBO:BioLifeSugarIncMember\n\n2025-12-31\n\n0001834105\n\nIBO:HappySugarIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:HappySugarIncMember\n\n2026-03-31\n\n0001834105\n\nIBO:HappySugarIncMember\n\n2025-12-31\n\n0001834105\n\nIBO:SweetSenseIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:SweetSenseIncMember\n\n2026-03-31\n\n0001834105\n\nIBO:SweetSenseIncMember\n\n2025-12-31\n\n0001834105\n\nIBO:GlobalSugarSolutionsIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:GlobalSugarSolutionsIncMember\n\n2026-03-31\n\n0001834105\n\nIBO:GlobalSugarSolutionsIncMember\n\n2025-12-31\n\n0001834105\n\nIBO:ImpactBiolifeScienceIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:ImpactBiolifeScienceIncMember\n\n2026-03-31\n\n0001834105\n\nIBO:ImpactBiolifeScienceIncMember\n\n2025-12-31\n\n0001834105\n\nIBO:DSSBiomedicalInternationalIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:DSSBiomedicalInternationalIncMember\n\n2026-03-31\n\n0001834105\n\nIBO:DSSBiomedicalInternationalIncMember\n\n2025-12-31\n\n0001834105\n\nIBO:DSSBiolifeInternationalIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:DSSBiolifeInternationalIncMember\n\n2026-03-31\n\n0001834105\n\nIBO:DSSBiolifeInternationalIncMember\n\n2025-12-31\n\n0001834105\n\n2021-02-19\n\n0001834105\n\n2021-02-19\n2021-02-19\n\n0001834105\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:CashMember\n\n2026-03-31\n\n0001834105\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:CashMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:FairValueMeasurementsRecurringMember\n\n2026-03-31\n\n0001834105\n\nus-gaap:FairValueMeasurementsRecurringMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:CashMember\n\n2025-12-31\n\n0001834105\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:CashMember\n\n2025-01-01\n2025-12-31\n\n0001834105\n\nus-gaap:FairValueMeasurementsRecurringMember\n\n2025-12-31\n\n0001834105\n\nus-gaap:FairValueMeasurementsRecurringMember\n\n2025-01-01\n2025-12-31\n\n0001834105\n\nus-gaap:DevelopedTechnologyRightsMember\n\n2026-03-31\n\n0001834105\n\nus-gaap:DevelopedTechnologyRightsMember\n\n2025-12-31\n\n0001834105\n\nIBO:AcquiredAssetsMember\nsrt:MinimumMember\n\n2026-03-31\n\n0001834105\n\nIBO:AcquiredAssetsMember\nsrt:MaximumMember\n\n2026-03-31\n\n0001834105\n\nIBO:AcquiredAssetsMember\n\n2026-03-31\n\n0001834105\n\nIBO:AcquiredAssetsMember\n\n2025-12-31\n\n0001834105\n\n2023-10-31\n\n0001834105\n\nus-gaap:SeriesAPreferredStockMember\n\n2023-10-31\n\n0001834105\n\n2023-10-31\n2023-10-31\n\n0001834105\n\nus-gaap:CommonStockMember\n\n2025-10-16\n2025-10-16\n\n0001834105\n\nIBO:EmployeesDirectorsAndConsultantsMember\n\n2024-10-01\n2024-10-01\n\n0001834105\n\nIBO:EmployeesDirectorsAndConsultantsMember\n\n2024-10-01\n\n0001834105\n\nIBO:CertainOfficersDirectorsAndConsultantsMember\n\n2024-10-01\n2024-10-01\n\n0001834105\n\nIBO:CertainOfficersDirectorsAndConsultantsMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nus-gaap:CommonStockMember\n\n2025-02-26\n2025-02-26\n\n0001834105\n\nus-gaap:CommonStockMember\n\n2025-09-23\n2025-09-23\n\n0001834105\n\nus-gaap:CommonStockMember\nIBO:DSSIncMember\n\n2025-10-16\n2025-10-16\n\n0001834105\n\n2026-01-01\n2026-01-31\n\n0001834105\n\nIBO:DSSIncMember\n\n2026-01-01\n2026-03-31\n\n0001834105\n\nIBO:DSSIncMember\n\n2025-01-01\n2025-03-31\n\n0001834105\n\nIBO:RevolvingPromissoryNoteMember\n\n2020-12-31\n\n0001834105\n\nIBO:RevolvingPromissoryNoteMember\n\n2020-12-31\n2020-12-31\n\n0001834105\n\n2020-12-31\n2020-12-31\n\n0001834105\n\n2020-12-31\n\n0001834105\n\nIBO:LiabilityComponentMember\n\n2025-03-31\n\n0001834105\n\nus-gaap:RelatedPartyMember\n\n2025-03-31\n\n0001834105\n\nus-gaap:RelatedPartyMember\n\n2025-10-16\n2025-10-16\n\n0001834105\n\nus-gaap:RelatedPartyMember\n\n2025-10-16\n\n0001834105\n\n2025-01-01\n2025-12-31\n\n0001834105\n\nIBO:DSSIncMember\nus-gaap:CommonStockMember\n\n2025-02-25\n2025-02-25\n\n0001834105\n\nIBO:DSSIncMember\n\n2025-12-31\n\n0001834105\n\nIBO:RoyaltyAgreementMember\n\n2018-08-14\n2018-08-15\n\n0001834105\n\nIBO:RoyaltyAgreementMember\nIBO:ChemiaCorporationMember\n\n2018-08-14\n2018-08-15\n\n0001834105\n\nIBO:RoyaltyAgreementMember\nIBO:ChemiaCorporationMember\n\n2018-11-26\n2018-11-27\n\n0001834105\n\nIBO:LicenseAgreementMember\n\n2022-03-18\n2022-03-19\n\n0001834105\n\nIBO:LicenseAgreementMember\n\n2022-03-19\n\n0001834105\n\nIBO:LicenseAgreementMember\n\n2026-03-31\n\n0001834105\n\nIBO:LicenseAgreementMember\n\n2025-12-31\n\n0001834105\n\nIBO:EmploymentAgreementMember\nIBO:FirstYearOfEmploymentTermMember\n\n2025-12-31\n\n0001834105\n\nIBO:EmploymentAgreementMember\nIBO:SecondYearOfEmploymentTermMember\n\n2025-12-31\n\n0001834105\n\nIBO:EmploymentAgreementMember\nIBO:ThirdYearOfEmploymentTermMember\n\n2025-12-31\n\n0001834105\n\nIBO:EmploymentAgreementMember\nIBO:MrHeuszelMember\n\n2026-03-31\n\n0001834105\n\nIBO:EmploymentAgreementMember\nIBO:TwoMrHeuszelMember\n\n2026-03-31\n\n0001834105\n\nIBO:EmploymentAgreementMember\nIBO:MrHeuszelMember\n\n2025-12-31\n\n0001834105\n\nIBO:EmploymentAgreementMember\nIBO:TwoMrHeuszelMember\n\n2025-12-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\nIBO:Segment\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n☒\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n**☐\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**333-275062**\n\nCommission\nfile number\n\n \n\n**Impact\nBioMedical, INC.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**Nevada**\n \n**85-3926944**\n\n(State\nor other Jurisdiction of\n \n(IRS\nEmployer\n\nincorporation-\nor Organization)\n \nIdentification\nNo.)\n\n \n\n**1400\nBroadfield Blvd., Suite 130,**\n\n**Houston,\nTX, 77084**\n\n(Address\nof principal executive offices)\n\n \n\n**(281)\n415-6576**\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted pursuant to Rule\n405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files) Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller\nreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer ☐\nAccelerated\nfiler ☐\nNon-accelerated\nfiler ☒\nSmaller\nreporting company ☒\n\n \n \n \n \n\nEmerging\ngrowth company ☒\n \n \n \n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\nTitle\nof each class\n \nTicker\nsymbol(s)\n \nName\nof each exchange on which registered\n\nCommon Stock, $0.001 par\nvalue per share\n \nN/A\n \nN/A\n\n \n\nAs\nof May 5, 2026 there were 107,821,231 shares of the registrant’s common stock, $0.001 par value, outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**IMPACT\nBIOMEDICAL, INC.**\n\n**FORM\n10-Q**\n\n**TABLE\nOF CONTENTS**\n\n \n\n**PART I**\n**FINANCIAL INFORMATION**"}